BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3476374)

  • 1. Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16.
    Berthold F; Creutzig U; Lampert F
    Haematol Blood Transfus; 1987; 30():406-9. PubMed ID: 3476374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
    Jehn U; Heinemann V
    Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
    Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
    Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.
    Hiddemann W; Urbanitz D; Preusser P; Achterrath W; Büchner T
    Hematol Oncol; 1989; 7(4):267-73. PubMed ID: 2737607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
    Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
    Hurwitz CA; Krance R; Schell MJ; Santana VM; Brenner MK; Ribeirio R; Roberts WM; Mahmoud H; Belt J; Crom W
    Leukemia; 1992; 6 Suppl 2():39-43. PubMed ID: 1374492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
    Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
    Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
    Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High dosage ARA-C in combination with mitoxantrone in therapy of acute myeloid leukemia in childhood. Initial results of the AML BFM-85 recurrence study].
    Ritter J; Creutzig U; Henze G; Jürgens H; Bode U; Prindull G; Schellong G
    Onkologie; 1987 Feb; 10(1):24-7. PubMed ID: 3295622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia.
    Loeb DM; Bowers DC; Civin CI; Friedman AD
    Med Pediatr Oncol; 2001 Oct; 37(4):365-71. PubMed ID: 11568900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
    Matsue K; Tohi T; Masauji N; Tsukuda K
    Rinsho Ketsueki; 1992 Mar; 33(3):338-42. PubMed ID: 1578638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
    Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
    Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
    Crews KR; Gandhi V; Srivastava DK; Razzouk BI; Tong X; Behm FG; Plunkett W; Raimondi SC; Pui CH; Rubnitz JE; Stewart CF; Ribeiro RC
    J Clin Oncol; 2002 Oct; 20(20):4217-24. PubMed ID: 12377965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
    Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
    Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.